Formulation development for pharmaceuticals
Evonik is a leader in drug delivery and is internationally recognized for its contributions to this field since the pioneering days of controlled release in the 1970s.
Central to our activities is the development of modified-release parenteral and oral products that systemically or locally deliver active pharmaceutical ingredients.
Our core competencies perfectly match today´s most important development targets in formulation development.
Oral drug delivery formulation development
With our more than 60 years experience we are exploring more effective routes of administration and are ultimately finding the formulation that turns a breakthrough treatment into a viable drug product.
Whether it's part of a full service project 'from drug substance to drug product' or you just want to link up with us for that specific leg of your timeline, formulating with Evonik makes sense.
We develop the full range of oral solid dosage forms, including monolithics and multiparticulates. Although our focus is on controlled drug release by film coating and matrix applications, we also cover the core development. Leveraging the functionalities of the EUDRAGIT® polymers and smart formulation techniques, we are able to tailor nearly every desired release profile to provide advanced drug delivery systems.
Get more information about EUDRAGIT®
Download your oral drug delivery services brochureBrochure
Parenteral drug delivery formulation development
Evonik formulation technologies and extended-release delivery systems enable virtually the entire spectrum of drugs – including peptides, proteins small molecules, antimetabolites, mitotic inhibitors, monoclonal antibodies – to be administered with greater precision over periods ranging from days to months, even years.
Evonik’s range of services expands beyond bioresorbable polymers, covering liposomes, conjugates and other complex approaches to meet your drug release profile, and optimize formulation.
Many of our extended-release microparticle formulations can be administered with a 25 to 27-gauge needle with smaller injection volumes for increased patient comfort and can be designed to deliver medicines continuously for a period from a few days up to six months. Conversely, implants are usually injected subcutaneously for systemic administration or into an anatomical space to provide high local concentration. Implant formulations can also be tailored to a targeted release profile in any mode of parenteral placement.
Typically, our drug delivery systems take the form of microparticles (micron-sized spheres of drug plus polymer) or implants (such as rods, etc.). All the microparticle and implant delivery systems developed by Evonik are bioabsorbable, breaking down into endogenous compounds completely and harmlessly at preprogrammed absorption rates. This is an especially important advantage for implants as it alleviates the need for removal surgery.
RESOMER® - tailored solutions for controlled and targeted parenteral release
When it comes to parenteral dosage forms, you can count on equally competent and committed assistance, and a technology platform that is an industry reference, to achieve your drug efficacy and processing efficiency objectives.
Our RESOMER® polymers, combined with microparticle and nanoparticle development and manufacturing expertise, including encapsulation, broaden the possibilities for controlled and targeted release - from minutes to months, with laser-like precision, whether it’s to deliver traditional actives or highly-potent APIs.
Parenteral dosage form development for:
Microparticles and nanoparticles
In-situ forming systems